Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2010

01-05-2010 | Poster presentation

CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapy

Authors: AM Thompson, S Bray, AM Johnson, P Quinlan, DM Nikloff, DG Evans, R Clarke, HJ Lawrence, A Howell, A Latif, R Ferraldeschl, G Hillman, M Fontecha, WG Newman

Published in: Breast Cancer Research | Special Issue 1/2010

Login to get access

Excerpt

Tamoxifen efficacy may be influenced by a number of factors, including CYP2D6 genotype, co-administration of drugs that inhibit CYP2D6, and adherence to tamoxifen therapy. CYP2D6 plays a major role in catalyzing the conversion of tamoxifen to its active metabolite endoxifen. Studies of the relevance of CYP2D6 genotyping have had conflicting results due to various limitations: differences in CYP2D6 allele coverage, phenotype classification and other confounding variables. …
Literature
1.
Schroth W, Antoniadou L, Fritz P, et al: Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007, 25: 5187-5193. 10.1200/JCO.2007.12.2705.CrossRefPubMed
Metadata
Title
CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapy
Authors
AM Thompson
S Bray
AM Johnson
P Quinlan
DM Nikloff
DG Evans
R Clarke
HJ Lawrence
A Howell
A Latif
R Ferraldeschl
G Hillman
M Fontecha
WG Newman
Publication date
01-05-2010
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2010
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2545

Other articles of this Special Issue 1/2010

Breast Cancer Research 1/2010 Go to the issue

Poster presentation

Breast calcification: the 'Cinderella' breast element?

Poster presentation

Thioredoxin and related redox systems as targets in breast cancer

Poster presentation

Identification of molecular subtypes within a formalin-fixed, paraffin-embedded breast cancer tumour cohort

Poster presentation

FKBPL: a novel prognostic and predictive biomarker?

Poster presentation

PLU-1/Jarid1B contributes to estrogen-induced cell proliferation in the normal mammary gland and in breast cancer, and is required for embryonic survival

Poster presentation

Recruitment of insulin receptor substrate-1 by erbB3 impacts on IGF-IR signalling in oestrogen receptor-positive breast cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits